Business Wire·Nov 11, 2026, 9:00 AM ET

PharmaCyte Biotech, Inc. Announces Reverse Stock Split

PharmaCyte Biotech's board approved a 1-for-19 reverse stock split ratified by stockholders on March 30, 2026.
The split legally takes effect at 4:01 p.m. Eastern Time on November 12, 2026.
Trading on a split-adjusted basis begins on November 13, 2026, under ticker "PMCB" with new CUSIP 71715X 302.
The company intends to regain compliance with Nasdaq's minimum bid price requirement through this action.
Every 19 existing shares convert to 1 new share, with no fractional shares issued.
Stockholders holding fractional shares receive cash payments based on the November 12, 2026 closing price.
Outstanding shares decrease from approximately 10,755,649 to 566,087, while the total authorized share count remains unchanged.
Exercise prices for stock options, warrants, convertible securities, incentive plan shares, are adjusted proportionally.
Electronic holders require no action, broker-held positions adjust automatically, physical certificate holders receive exchange instructions from Equiniti Trust Company.